Form 4 Filing for David Matthew T

On October 14, 2026, David Matthew T, Chief Financial Officer of Actinium Pharmaceuticals, Inc. (ATNM), was granted 250,000 Restricted Stock Units (RSUs) and an option to purchase 250,000 shares of common stock. The RSUs vest in installments over three years, contingent on continued service. The stock options vest over time, with 28% vesting after 12 months and 2% monthly thereafter, also contingent on continued service. The exercise price for the stock options is $0.9750 per share. Mr. David reported direct ownership of 250,000 shares of common stock and 250,000 stock options following these transactions.